You have no items in your shopping cart.
Description
Recombinant human IL-1β protein, a high-purity pro-inflammatory cytokine produced in an E. coli expression system and precisely refolded to retain its native bioactivity, exerts a central role in innate immune defense, tissue damage response, and acute-phase reactions by binding to the IL-1RI receptor (signal transduction) and the IL-1RII decoy receptor (negative regulation), thereby activating the NF-κB and MAPK signaling axes and inducing the cascade release of inflammatory mediators such as IL-6 and COX-2.
Its activity is competitively inhibited by the endogenous IL-1 receptor antagonist (IL-1RA), a regulatory mechanism critically implicated in chronic inflammatory diseases like rheumatoid arthritis and β-cell destruction in diabetes.
In cell therapy, IL-1β serves as a key factor for in vitro stem cell activation: low-dose pulse stimulation enhances the immunomodulatory function of mesenchymal stem cells (MSCs), promoting their secretion of prostaglandin E2 (PGE2) and hepatocyte growth factor (HGF), thereby optimizing the reparative efficacy of MSC grafts for ischemia-reperfusion injury or fibrotic diseases.
Simultaneously, in tumor immunotherapy, modulation of the IL-1β signaling pathway can improve the infiltration and persistence of CAR-T cells within the solid tumor microenvironment.
Specifications
| Specification | Acceptance Criteria | Results |
|---|---|---|
| Appearance | Freeze-dried preparation, the form should be white loose body | Compliance |
| Identity | The electrophoretic bands should be consistent with the molecular weight of the product | Compliance |
| Visible Particle | Should be no visible particle | Compliance |
| Moisture | ≤4.0% | 0.7% |
| pH | 6.5~7.5 | 7.2 |
| Purity | >90.0% | Compliance |
| Endotoxin | <0.1EU/μg | <0.1EU/μg |
| Mycoplasma | Should be negative | Negative |
| Sterility | No growth | No growth |
| Biological Activity | Inducing IFN-y secretion in human natural killer lymphoma NK-92 cells through its induction Ability determination, corresponding specific activity ≥1x107IU/mg | 5.36x107 IU/mg |
Features
-
✔ High Biological Activity
Specific activity ≥ 1×107 IU/mg, validated by NK-92 IFN-γ secretion assay.
-
✔ High Purity & Low Endotoxin
>90% purity (SDS-PAGE) with endotoxin <0.1 EU/μg, mycoplasma negative and sterile.
-
✔ Precisely Refolded E. coli Expression
Engineered and refolded to retain native bioactivity and receptor-binding functionality.
-
✔ Validated Batch Quality
Tested for identity, moisture, pH, sterility, and biological activity to ensure lot-to-lot consistency.
Applications
T Cell Research
Modulation of IL-1β signaling to investigate T-cell activation and tumor microenvironment dynamics.
MSC Activation Studies
Low-dose stimulation to enhance MSC immunomodulatory secretion (e.g., PGE2, HGF).
Inflammation & Cytokine Signaling Research
NF-κB/MAPK pathway studies and downstream mediator induction analysis.
Tumor Immunotherapy Models
Research on CAR-T infiltration and persistence within solid tumor environments.
Stability & Storage
- Lyophilized powder: Stable for 12 months at −80 °C or 6 months at −20 °C when stored in the original sealed container under desiccant.
- Reconstitution: Dissolve in sterile water for injection, 0.9% NaCl, or PBS (pH 7.4), maintaining a final concentration ≥ 100 µg/mL to prevent adsorption.
- Handling: Aliquot to avoid repeated freeze–thaw cycles.
Cautions
• Research Use Only: This product is not intended for diagnostic or therapeutic use.
• Handling: Prepare solutions using sterile technique. Avoid microbial contamination to maintain activity.
• Storage: Follow recommended storage conditions. Repeated freeze–thaw cycles may reduce performance.
Documents
When can I expect my order to ship?
Most orders are filled and shipped within 2-3 business days from the time they are received.
Our standard shipping usually take 2-5 days.
We also provide express shippping for time-sensitive deliveries.
Email contact@biofargo.com if you have any requirements.

